Clinical trials: CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP.
- Trial name
- NCT06747351
- Testing
- TAK-881, HYQVIA, SC Investigational Needle Sets
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy is a diffuse multifocal autoimmune disorder of the peripheral neuron, affecting 1 to 9 in 100,000 people.
- Trial name
- SW_CIDP (NCT04529291)
- Testing
- Group with walking disorder, Group without walking disorder
- Sponsor
- Fondation Hôpital Saint-Joseph
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson
Chronic Inflammatory Demyelinating Polyneuropathy
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199).
- Trial name
- NCT07188844
- Testing
- Batoclimab
- Where
- 30 sites in United States, Argentina and 9 more
- Volunteers
- 26 people
- Sponsor
- Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV).
- Trial name
- POINT (NCT01225276)
- Testing
- NewGam 10%
- Volunteers
- 2 people
- Sponsor
- Octapharma
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.
- Trial name
- NCT02955355
- Testing
- HYQVIA
- Where
- 35 sites in United States, Argentina and 16 more
- Volunteers
- 85 people
- Sponsor
- Baxalta now part of Shire
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and often disabling neuropathy that often responds to immune therapies.
- Trial name
- NCT05877040
- Testing
- Rituximab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Clinico Humanitas
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06939166
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tianjin Huanhu Hospital
Chronic Inflammatory Demyelinating Polyneuropathy
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy is disease believed to be due to immune cells, cells which normally protect the body, but are now attacking the nerves in the body.
- Trial name
- NCT00278629
- Testing
- hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Northwestern University
Guillain Barré Syndrome
Upper Limb Robot-Assisted Therapy in Patients With Guillain-Barré Syndrome
Guillain-Barré Syndrome is an immune-mediated polyradiculoneuropathy, with around 100,000 new cases reported worldwide annually.
- Trial name
- RAUL-Project (NCT06620198)
- Testing
- Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming, Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Panzyga in CIDP Administered at Different Infusion Rates
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause.
- Trial name
- Panzyga-CIDP (NCT03166527)
- Testing
- Immune Globulin 10% Intravenous Solution
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Vera Bril
Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of Telitacicept in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- NCT07597733
- Testing
- Conventional Therapy, Telitacicept
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Academy of Medical Sciences
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are…
- Trial name
- HYbISCUE (NCT06538064)
- Testing
- No Intervention
- Where
- 15 sites in United States, Denmark and 1 more
- Volunteers
- 30 people
- Sponsor
- Takeda
Polyneuropathy, Inflammatory Demyelinating, Chronic
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual…
- Trial name
- ORBIT-CIDP (NCT06968975)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sanofi
Charcot-Marie-Tooth, CMT1A
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals…
- Conditions
- Charcot-Marie-Tooth, CMT1A, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)
- Trial name
- CMT-NFS (NCT07461896)
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta